Corporate Governance

INVESTORS & MEDIA

INVESTORS
& MEDIA

Corporate Governance

The Board of Directors of Regeneron Pharmaceuticals, Inc. (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.

Committee Composition

  Audit Compensation Corporate Governance and Compliance Technology
P. Roy Vagelos, M.D.
Image of P. Roy Vagelos, M.D.
P. Roy Vagelos, M.D.
Retired Chairman of the Board and Chief Executive Officer, Merck & Co. Inc.

P. Roy Vagelos, MD, has been Chairman of the Board of the Company since January 1995. Prior to joining Regeneron, Dr. Vagelos was Chairman of the Board and Chief Executive Officer of Merck & Co., Inc. He joined Merck in 1975, became a director in 1984, President and Chief Executive Officer in 1985, and Chairman in 1986. Dr. Vagelos retired from all positions with Merck in 1994. Dr. Vagelos was on the Board of Directors of Theravance, Inc. through April 2010.

      Member of the Technology Committee
Charles A. Baker
Image of Charles A. Baker
Charles A. Baker
Retired Chairman of the Board, President and Chief Executive Officer of The Liposome Company, Inc.

Charles A. Baker has been a Director of the Company since February 1989. In September 2000, Mr. Baker retired as Chairman, President, and Chief Executive Officer of The Liposome Company, Inc., a position he had held since December 1989. During his career, Mr. Baker served in a senior management capacity in various pharmaceutical companies, including tenures as Group Vice President, Squibb Corporation (now Bristol-Myers Squibb) and President, Squibb International, and various senior executive positions at Abbott Laboratories and Pfizer, Inc. Mr. Baker currently is a member of the Board of Directors of Progenics Pharmaceuticals, Inc.

Member of the Audit Committee Member of the Compensation Committee    
Bonnie L. Bassler, Ph.D.
Bonnie L. Bassler, Ph.D.
Chair, Department of Molecular Biology, and Squibb Professor in Molecular Biology, Princeton University
Bonnie L. Bassler, Ph.D., joined the Board in September 2016. Dr. Bassler is the Chair of the Department of Molecular Biology and the Squibb Professor in Molecular Biology at Princeton University, and a Howard Hughes Medical Institute Investigator. Dr. Bassler has previously served on the Boards for the American Association for the Advancement of Science, the National Science Foundation and the American Academy of Microbiology. Dr. Bassler also served as the President of the American Society for Microbiology. She has been elected to the National Academy of Sciences, the American Academy of Arts and Sciences, the Royal Society and the American Philosophical Society. Dr. Bassler has received many scientific honors, including a MacArthur Foundation Fellowship, the Lounsbery Award and the Shaw Prize for Life Science and Medicine.
 
Dr. Bassler received her B.Sc. from the University of California, Davis, and her Ph.D. in Biochemistry from the Johns Hopkins University. She served as a Postdoctoral Fellow and Research Scientist at the Agouron Institute in La Jolla, California, before becoming a faculty member at Princeton University.
    Member of the Corporate Governance and Compliance Committee Member of the Technology Committee
Michael S. Brown, M.D.
Image of Michael S. Brown, M.D.
Michael S. Brown, M.D.
Regental Professor of Molecular Genetics and Internal Medicine,
Director, Jonsson Center for Molecular Genetics
The University of Texas Southwestern Medical Center at Dallas

Michael S. Brown, M.D., has been a Director of the Company since June 1991. Dr. Brown holds the Distinguished Chair in Biomedical Sciences, a position he has held since 1989, is a Regental Professor of Molecular Genetics and Internal Medicine, and the Director of the Jonsson Center for Molecular Genetics at the University of Texas Southwestern Medical Center at Dallas, positions he has held since 1985. Dr. Brown and Dr. Joseph Goldstein jointly received the Nobel Prize for Physiology or Medicine in 1985. Dr. Brown is a member of the National Academy of Sciences, the Institute of Medicine and Foreign Member of the Royal Society (London).  Dr. Brown served as a member of the Board of Directors of Pfizer Inc.until April 2012.

    Member of the Corporate Governance and Compliance Committee Chair of the Technology Committee
Tony Coles
Tony Coles
Chairman and Chief Executive Officer, Yumanity Therapeutics, LLC

Dr. Coles, age 56, has served as Chairman and Chief Executive Officer of Yumanity Therapeutics, LLC, a company focused on transforming drug discovery for neurodegenerative diseases, since October 2014. Prior to this, from October 2013, Dr. Coles served as Chairman and CEO of TRATE Enterprises LLC, a privately held company. Dr. Coles served as President, Chief Executive Officer and Chairman of the Board of Onyx Pharmaceuticals, Inc., a biopharmaceutical company, from 2012 until 2013, having served as its President, Chief Executive Officer and a member of its board of directors from 2008 until 2012. Prior to joining Onyx in 2008, he was President, Chief Executive Officer, and a member of the board of directors of NPS Pharmaceuticals, Inc., a biopharmaceutical company. Before joining NPS in 2005, he served in various leadership positions in the biopharmaceutical and pharmaceutical industries, including at Merck & Co., Inc., Bristol-Myers Squibb Company, and Vertex Pharmaceuticals Incorporated. In addition to having previously served as a director of Onyx and NPS, he was formerly a director of Laboratory Corporation of America Holdings and Campus Crest Communities, Inc. Dr. Coles has been a director of McKesson Corporation since April 2014 and serves on the Compensation Committee and the Finance Committee of its board of directors.  He has also served as Chairman of the board of directors of CRISPR Therapeutics AG since October 2015 and serves on its Compensation Nomination and Corporate Governance Committee.

Member of the Audit Committee      
Joseph L. Goldstein, M.D.
Image of Joseph L. Goldstein, M.D.
Joseph L. Goldstein, M.D.
Regental Professor and Chairman, Department of Molecular Genetics The University of Texas Southwestern Center at Dallas

Joseph L. Goldstein, MD, has been a Director of the Company since June 1991. Dr. Goldstein has been Professor of Medicine and Genetics and Chairman of the Department of Molecular Genetics at The University of Texas Southwestern Medical Center at Dallas since 1977. Dr. Goldstein is a member of the National Academy of Sciences. Drs. Goldstein and Brown jointly received the Nobel Prize for Physiology or Medicine in 1985.

  Member of the Compensation Committee   Member of the Technology Committee
Christine A. Poon
Image of Christine A. Poon
Christine A. Poon
Professor in the Department of Management and Human Resources Max M. Fisher College of Business at The Ohio State University

Christine A. Poon has been a director of the Company since 2010. Ms. Poon is a professor in the Department of Management and Human Resources at The Max M. Fisher College of Business at The Ohio State University, where she served as Dean and the John W. Berry, Sr. Chair in Business from 2009 to 2014. Prior to joining Fisher, Ms. Poon spent 30 years in the healthcare industry, most recently as vice chairman and worldwide chairman of pharmaceuticals at Johnson & Johnson, where she served on the company's Board of Directors and Executive Committee and was responsible for managing the pharmaceutical businesses of the company. Her areas of expertise include domestic and international business operations and sales and marketing. Prior to joining Johnson & Johnson, she spent 15 years at Bristol-Myers Squibb. Ms. Poon is on the Board of Directors of Prudential Financial, Inc. and the Supervisory Board of Royal Philips Electronics. She was named Woman of the Year by the Healthcare Businesswomen's Association in 2004 and named Business Leader of the Future by CNBC/Wall Street Journal in 2005.

  Chair of the Compensation Committee Member of the Corporate Governance and Compliance Committee  
Arthur F. Ryan
Image of Arthur F. Ryan
Arthur F. Ryan
Retired Chairman of the Board and Chief Executive Officer Prudential Financial, Inc.

Arthur F. Ryan has been a Director of the Company since January 2003. In 2008 Mr. Ryan retired as the Chairman and Chief Executive Officer of Prudential Financial, Inc., one of the largest diversified financial institutions in the world. Prior to joining Prudential in December 1994, Mr. Ryan served as President and Chief Operating Officer of Chase Manhattan Bank since 1990. Mr. Ryan ran Chase’s worldwide retail bank between 1984 and 1990. From 2008 to 2013, Mr. Ryan served as a non-executive director of the Royal Bank of Scotland Group plc.

Member of the Audit Committee   Chair of the Corporate Governance and Compliance Committee  
Leonard S. Schleifer, M.D., Ph.D.
Image of Leonard S. Schleifer, M.D., Ph.D.
Leonard S. Schleifer, M.D., Ph.D.
President and Chief Executive Officer

Leonard S. Schleifer, M.D., Ph.D., founded the Company in 1988, has been a Director and its President and Chief Executive Officer since its inception, and served as Chairman of the Board from 1990 through 1994. From 1984 to 1988 he was Assistant Professor at Cornell University Medical College in the Departments of Neurology and Neurobiology. Dr. Schleifer received his MD and PhD in Pharmacology from the University of Virginia. Dr. Schleifer is a licensed physician and is certified in neurology by the American Board of Psychiatry and Neurology.

      Member of the Technology Committee
George L. Sing
Image of George L. Sing
George L. Sing
Managing Director, Lancet Capital

George L. Sing has been a Director of the Company since January 1988. Since 1998, he has been a Managing Director of Lancet Capital, a venture capital investment firm in the healthcare field. From January 2004 to April 2015,  Mr. Sing served as Chief Executive Officer of Stemnion, Inc., a bio-medical company in the regenerative medicine field.


 

Chair of the Audit Committee Member of the Compensation Committee    
Marc Tessier-Lavigne, Ph.D.
Marc Tessier-Lavigne, Ph.D.
President, Stanford University

Marc Tessier-Lavigne, Ph.D., has been a Director of the Company since November 2011. Dr. Tessier-Lavigne was appointed as the President of Stanford University in September 2016. From March 2011 to August 2016, he served as the President of The Rockefeller University. Previously, he served as Executive Vice President and Chief Scientific Officer at Genentech, which he joined in 2003. He was a professor at Stanford from 2001 to 2003 and at the University of California, San Francisco from 1991 to 2001. Dr. Tessier-Lavigne, a leader in the field of brain development, is a member of the National Academy of Sciences and its Institute of Medicine and a fellow of the Royal Societies of the United Kingdom and Canada.

      Member of the Technology Committee
George D. Yancopoulos, M.D., Ph.D.
Image of George D. Yancopoulos, M.D., Ph.D.
George D. Yancopoulos, M.D., Ph.D.
Founding Scientist, President, Regeneron Laboratories & Chief Scientific Officer

George D. Yancopoulos, M.D., Ph.D., has been President, Regeneron Laboratories and Chief Scientific Officer since December 2000 and a Director since 2001. Prior to that date, he was Senior Vice President, Research, a position he held since June 1997, and Chief Scientific Officer, a position he held since January 1998. Dr. Yancopoulos was Vice President Discovery from January 1992 until June 1997, and Head of Discovery from January 1991 to January 1992. He joined Regeneron in March 1989 as its founding scientist. He received his Ph.D. in Biochemistry and Molecular Biophysics and his M.D. from Columbia University. Dr. Yancopoulos is a member of the National Academy of Sciences.

      Member of the Technology Committee
Huda Y. Zoghbi, M.D.
Huda Y. Zoghbi, M.D.
Professor, Departments of Pediatrics, Molecular & Human Genetics, and Neurology & Neuroscience, Baylor College Director, Jan & Dan Duncan Neurological Research Institute at Texas Children's Hospital
Huda Y. Zoghbi, M.D., joined the Board in September 2016. Dr. Zoghbi is a professor in the departments of Pediatrics, Molecular and Human Genetics, and Neurology and Neuroscience at Baylor College of Medicine, the director of the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, and an investigator of the Howard Hughes Medical Institute. Dr. Zoghbi has been elected to the National Academy of Sciences, the Institute of Medicine and the American Association for the Advancement of Science. She has been awarded numerous recognitions for her work including the Pearl Meister Greengard Prize, the March of Dimes Prize in Developmental Biology and the Vanderbilt Prize in Biomedical Science.
 
Dr. Zoghbi earned her B.Sc. from the American University of Beirut, received her M.D. from Meharry Medical College in Nashville, Tennessee, and completed her pediatrics residency and a joint residency in neurology and pediatric neurology at Baylor College of Medicine, where she then pursued postdoctoral research training in molecular genetics.
    Member of the Corporate Governance and Compliance Committee Member of the Technology Committee
= Chair
= Member

Contact the Board

You can contact Regeneron Pharmaceuticals, Inc.'s Board of Directors to provide comments, to report concerns, or to ask a question, at the following address.

Corporate Secretary
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
United States

You may submit your concern anonymously or confidentially by postal mail. You may also indicate whether you are a shareholder, customer, supplier, or other interested party.

Communications are distributed to the Board, or to any individual directors as appropriate, depending on the facts and circumstances outlined in the communication. In that regard, the Regeneron Pharmaceuticals, Inc. board of directors has requested that certain items which are unrelated to the duties and responsibilities of the board should be excluded, such as:

  • Product complaints
  • Product inquiries
  • New product suggestions
  • Resumes and other forms of job inquiries
  • Surveys
  • Business solicitations or advertisements

In addition, material that is unduly hostile, threatening, illegal or similarly unsuitable will be excluded, with the provision that any communication that is filtered out must be made available to any non-management director upon request.

You may also communicate online with our Board of Directors as a group.

Please submit your question using the form below.

* Indicates required field

Insider Transactions

Corporate Governance
Date Name Title Type Shares Traded Price Range
Dec 17, 2007 yancopoulos george Officer Acquisition (Non Open Market) 500,000 n/a
Dec 12, 2007 gilman alfred g Director Disposition (Non Open Market) 2,000 n/a
Nov 20, 2007 roberts william Officer Acquisition (Non Open Market) 34,684 n/a
Nov 20, 2007 vagelos p roy Director Automatic Sell 138,737 n/a
Nov 6, 2007 brown michael s Director Automatic Sell 6,108 19.42 - 20.08
Nov 5, 2007 brown michael s Director Automatic Sell 13,292 20.31 - 20.66
Nov 5, 2007 brown michael s Director Option Execute 10,000 7.91
Nov 5, 2007 brown michael s Director Automatic Sell 600 20.67 - 20.87
Nov 5, 2007 goldstein joseph l Director Automatic Sell 4,200 20.38 - 20.63
Nov 5, 2007 goldstein joseph l Director Option Execute 4,200 7.66
Nov 5, 2007 goldstein joseph l Director Automatic Sell 800 20.64 - 20.87
Nov 5, 2007 goldstein joseph l Director Option Execute 800 7.66
Nov 2, 2007 mccorkle douglas s Officer Automatic Sell 6,209 21.00 - 21.03
Nov 2, 2007 mccorkle douglas s Officer Option Execute 6,209 8.50 - 9.49
Oct 2, 2007 shooter eric m Director Sell 10,000 18.30 - 18.37
Oct 2, 2007 shooter eric m Director Option Execute 10,000 7.66
Oct 1, 2007 vagelos p roy Director Automatic Sell 11,560 n/a
FirstPrevious
...
43

Stock transaction information provided by EDGAR Online. Regeneron Pharmaceuticals, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.